Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nuvectis Pharma (NVCT) Research & Development (2021 - 2026)

Nuvectis Pharma has reported Research & Development over the past 6 years, most recently at $4.1 million for Q1 2026.

  • Quarterly results put Research & Development at $4.1 million for Q1 2026, up 11.58% from a year ago — trailing twelve months through Mar 2026 was $18.6 million (up 33.3% YoY), and the annual figure for FY2025 was $18.2 million, up 40.52%.
  • Research & Development reached $4.1 million in Q1 2026 per NVCT's latest filing, down from $5.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.8 million in Q3 2025 and bottomed at $865000.0 in Q1 2022.
  • Median Research & Development over the past 5 years was $4.1 million (2026), compared with a mean of $3.7 million.
  • Peak annual rise in Research & Development hit 284.35% in 2022, while the deepest fall reached 40.99% in 2022.
  • Over 5 years, Research & Development stood at $4.4 million in 2022, then dropped by 3.0% to $4.3 million in 2023, then grew by 5.42% to $4.5 million in 2024, then rose by 13.12% to $5.1 million in 2025, then dropped by 19.27% to $4.1 million in 2026.
  • Business Quant data shows Research & Development for NVCT at $4.1 million in Q1 2026, $5.1 million in Q4 2025, and $5.8 million in Q3 2025.